Journal of drugs in dermatology : JDD · 2025
Glucagon-Like Peptide-1 Receptor Agonists Reduce Surgeries and Hospitalizations in Hidradenitis Suppurativa: A Multicenter TriNetX Cohort Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gupta Neal, Zafar Kayla, Patel Paras, Kabakova Margaret, Collins Alexia, Ray Maile, Shayya Ashley, McGinnis Sandra, Kurtti Alana, Cohen Marc, Austin Evan, Derrick Kristina, Glick Sharon, Jagdeo Jared
Аннотация
BACKGROUND: Hidradenitis suppurativa is a chronic inflammatory skin condition frequently associated with type 2 diabetes mellitus and obesity. Glucagon-like peptide-1 receptor agonists have emerged as promising agents for managing type 2 diabetes mellitus due to their potent effects on glycemic control and weight reduction. Recent evidence suggests that glucagon-like peptide-1 receptor agonists may also possess anti-inflammatory properties, potentially making them effective in treating inflammatory conditions, such as hidradenitis suppurativa.
OBJECTIVE: To determine if glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in patients with hidradenitis suppurativa.
METHODS: We utilized the TriNetX platform to evaluate the rate of surgical abscess repairs performed and hospitalizations in a propensity score-matched cohort of patients with hidradenitis suppurativa who were prescribed glucagon-like peptide-1 receptor agonists.
RESULTS: Our analysis revealed that patients prescribed glucagon-like peptide-1 receptor agonists had significantly lower rates of surgeries with a HR of 0.35 (95% CI: 0.25, 0.50) and hospitalizations with a HR of 0.87 (95% CI: 0.82, 0.92) compared to a control cohort of patients who did not receive glucagon-like peptide-1 receptor agonists.
CONCLUSIONS: Glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa, demonstrating their potential therapeutic value in dermatology patient care.
OBJECTIVE: To determine if glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in patients with hidradenitis suppurativa.
METHODS: We utilized the TriNetX platform to evaluate the rate of surgical abscess repairs performed and hospitalizations in a propensity score-matched cohort of patients with hidradenitis suppurativa who were prescribed glucagon-like peptide-1 receptor agonists.
RESULTS: Our analysis revealed that patients prescribed glucagon-like peptide-1 receptor agonists had significantly lower rates of surgeries with a HR of 0.35 (95% CI: 0.25, 0.50) and hospitalizations with a HR of 0.87 (95% CI: 0.82, 0.92) compared to a control cohort of patients who did not receive glucagon-like peptide-1 receptor agonists.
CONCLUSIONS: Glucagon-like peptide-1 receptor agonists reduce surgeries and hospitalizations in hidradenitis suppurativa, demonstrating their potential therapeutic value in dermatology patient care.